DAX24.250 +0,1%ESt505.390 +0,2%Top 10 Crypto16,17 +1,7%Dow44.633 -0,5%Nas21.098 -0,4%Bitcoin102.625 +0,5%Euro1,1541 -0,1%Öl71,78 -1,4%Gold3.328 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F Heidelberger Druckmaschinen 731400 NVIDIA 918422 Rheinmetall 703000 Mercedes-Benz Group (ex Daimler) 710000 PayPal A14R7U RENK RENK73 BASF BASF11 Lufthansa 823212 BYD A0M4W9 DroneShield A2DMAA Deutsche Bank 514000 Tesla A1CX3T Volkswagen (VW) vz. 766403 Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Vor Fed-Zinsentscheid: DAX wenig bewegt -- Mercedes-Benz passt nach schwachem Quartal Prognose an -- D-Wave, DroneShield, Microsoft, Novo Nordisk, BYD, Porsche, adidas, BASF, Rüstungswerte im Fokus
Top News
Kryptokurse am Mittwochmittag Kryptokurse am Mittwochmittag
L'Oréal-Aktie höher: Umsatzanstieg im ersten Halbjahr L'Oréal-Aktie höher: Umsatzanstieg im ersten Halbjahr
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Roche Aktie

Handeln
279,05 EUR +0,35 EUR +0,13 %
FSE
259,70 CHF +0,20 CHF +0,08 %
SWX
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.222,08 Mrd. EUR

KGV24,60Div. Rendite3,80%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN855167

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCH0012032048

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRHHVF

Roche Aktien News

DatumMeistgelesen
PR NewswireRoche joins forces with the U.S. Centers for Disease Control and Prevention to strengthen laboratory systems in the fight against the HIV and tuberculosis epidemics
PR NewswireRoche joins forces with the U.S. Centers for Disease Control and Prevention to strengthen laboratory systems in the fight against the HIV and tuberculosis epidemics
GlobeNewswireRoche launches two new antibodies to identify key clinical mutations in patients with brain cancer
GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Transaction in Roche bearer shares
GlobeNewswireNew phase III data show Roche’s Vabysmo rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO)
PR NewswireRoche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics
PR NewswireJana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease
PR NewswireNew Survey Shows Many Americans Are Confused by Testing Options for COVID-19 and Flu
PR NewswireRoche Announces Brad Moore as President and CEO of Roche Diagnostics North America
PR NewswireJnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases
PR NewswireRoche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE
GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease
PR NewswireRoche launches Pilot brand, expands retail channels for COVID-19 At-Home Test
GlobeNewswireSTRONG-HF study results demonstrate clear benefits for acute heart failure patients
PR NewswireRoche introduces the navify brand for its digital health solutions at HLTH 2022
PR NewswireRoche introduces the navify brand for its digital health solutions at HLTH 2022
PR NewswireRoche introduces the navify brand for its digital health solutions at HLTH 2022
PR NewswireRoche introduces the navify brand for its digital health solutions at HLTH 2022
PR NewswireRoche introduces the navify brand for its digital health solutions at HLTH 2022
GlobeNewswireRoche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs
GlobeNewswirePositive topline phase III results show Roche's Vabysmo improved vision for people living with retinal vein occlusion (RVO)
GlobeNewswireEarly treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile
GlobeNewswireRoche receives FDA clearance for COVID-19 PCR test for use on cobas 6800/8800 Systems
GlobeNewswireRoche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022
GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
GlobeNewswireRoche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use
GlobeNewswirePositive new data for Roche’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)
GlobeNewswireRoche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma
GlobeNewswireRoche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
GlobeNewswireRoche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU
GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Corporate Executive Committee in January 2023
PR NewswireRoche launches its next-generation SARS-CoV-2 Rapid Antibody Test
GlobeNewswireChange in the Roche Board of Directors
PR NewswireRoche granted FDA clearance for cobas pure integrated solutions for low- to mid-volume laboratories
GlobeNewswireEuropean Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss
PR NewswireRoche's VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo
PR NewswireRoche's VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo
PR NewswireRoche's VENTANA PD-L1 (SP263) test gains CE label expansion as a companion diagnostic to identify non-small cell lung cancer patients eligible for Tecentriq
PR NewswireRoche's VENTANA PD-L1 (SP263) test gains CE label expansion as a companion diagnostic to identify non-small cell lung cancer patients eligible for Tecentriq
GlobeNewswireRoche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.